Orion Oyj (OTCMKTS:ORINY - Get Free Report) announced a dividend on Monday, March 17th, NASDAQ Dividends reports. Shareholders of record on Monday, April 7th will be given a dividend of 0.4478 per share on Tuesday, April 29th. The ex-dividend date of this dividend is Monday, April 7th. This is a 86.2% increase from Orion Oyj's previous dividend of $0.24.
Orion Oyj Price Performance
Shares of ORINY stock remained flat at $30.57 during trading on Friday. 145 shares of the stock were exchanged, compared to its average volume of 3,307. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The firm's 50 day moving average is $27.42 and its two-hundred day moving average is $25.59. The stock has a market capitalization of $8.63 billion, a P/E ratio of 24.26 and a beta of 0.25. Orion Oyj has a twelve month low of $17.50 and a twelve month high of $30.57.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The company had revenue of $463.41 million during the quarter. Research analysts anticipate that Orion Oyj will post 1.18 EPS for the current year.
Analysts Set New Price Targets
Separately, Nordea Equity Research downgraded shares of Orion Oyj to a "hold" rating in a research report on Tuesday, February 4th.
Check Out Our Latest Stock Report on Orion Oyj
Orion Oyj Company Profile
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
See Also
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
